Clinical Accelerator and Metavention have recently entered into a collaboration allowing Clinical Accelerator to join the program of feasibility studies already under way in the United States, New Zealand and Australia. Our organization will participate in the renal denervation trial of Metavention’s novel device to evaluate safety and effectiveness in patients with hypertension. With Clinical Accelerator’s strong focus on advancing cardiovascular medical devices, this is a very exciting project for our team to participate in and attain quality data for.
Metavention has developed a unique Integrated Radio Frequency (iRF) Denervation System, which is currently under investigation for renal, hepatic and multi-organ denervation – a novel intravascular procedure. Designed to be a one time, minimally invasive procedure, the device uses radio frequency energy to disrupt over active sympathetic nerves. The use of this advanced technology in conditions like hypertension and type 2 diabetes is hypothesized to reduce blood pressure, improve blood sugar control and improve other metabolic disease such as non-alcoholic fatty liver disease (NAFLD).
About Clinical Accelerator
Clinical Accelerator is a boutique academically oriented clinical CRO focused on the needs of emerging MedTech companies. The organization has a strong emphasis on cardiovascular indications and performs clinical investigations of novel cardiac devices. Studies are mostly implemented in Central and Eastern Europe, a region with well-known advantages for clinical trials such as – fast start-up timelines and good access to patients. Clinical Accelerator aims to accelerate clinical development programs of international medical technology companies through early entry into the clinic and fast and efficient implementation of both feasibility and pivotal clinical investigations.
Metavention, Inc. is a privately-held medical device company headquartered in Minneapolis, Minnesota and the developer of the iRF Denervation System, a novel technology designed to disrupt the sympathetic nerves that contribute to type 2 diabetes, high blood pressure, and other metabolic diseases.
CAUTION: The iRF Denervation System is not approved for sale in any region and is limited by Federal (US) Law to investigational use only.
You must be logged in to post a comment.